This article is part of a Chronicle. See more from this Chronicle
Thomas Cueni, Nov 12, 2008
While the pharmaceutical sector waits for the European Commission’s interim report and hearing scheduled for November 28, 2008, there is an opportunity to step back and examine critically the premise of the inquiry started infamously with dawn raids on January 16, 2008 that, as Commissioner Kroes announced, “if innovative products are not being produced, and cheaper generic alternatives delay
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.138.134.163
Please verify email or join us to access premium content!